← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Stemina Biomarker Discovery, Inc.
Madison, WI
$6,550,113
Total funding
7
Grants
Funding over time
peak $1.6M · FY2008–23$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,197,547 · 5
NSF$1,102,623 · 1
FDA$249,943 · 1
By mechanism
R44$3,901,417 · 2
—$1,102,623 · 1
N44$999,936 · 1
U01$249,943 · 1
N43$149,528 · 1
R43$146,666 · 1
Investigators at Stemina Biomarker Discovery, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
SBIR Phase II: Metabolomics of Human Embryonic Stem Cells to Predict Teratogenicity: An Alternative Developmental Toxicity Model$1,102,623
· FY2011 · TIP
TAS::75 0849::TAS$999,936
N44 · FY2010 · CA
A Metabolism-Based Test to Diagnose Autism Spectrum Disorder and its Subtypes in Early Childhood$894,684
R44 · FY2016 · MH
A Metabolism-Based Test to Diagnose Autism Spectrum Disorder and its Subtypes in Early Childhood$892,872
R44 · FY2015 · MH
A Metabolism-Based Test to Diagnose Autism Spectrum Disorder and its Subtypes in Early Childhood$859,582
R44 · FY2017 · MH
Identification of Biomarkers of Cardiotoxicity using Metabolomics of Human Pluripotent Stem Cell-Derived Cardiomyocytes$742,776
R44 · FY2015 · GM
Identification of Biomarkers of Cardiotoxicity using Metabolomics of Human Pluripotent Stem Cell-Derived Cardiomyocytes$511,503
R44 · FY2016 · GM
DDT-BMQ-000109, Qualification of biomarkers for in vitro developmental toxicity screening in a human system$249,943
U01 · FY2023 · FD
Predictive Efficacy Screening in Cancer Stem Cells$149,528
N43 · FY2008 · CA
Identification of Biomarkers of Cardiotoxicity using Metabolomics of Human Plurip$146,666
R43 · FY2012 · GM